{
  "id": 20332324,
  "title": "Where Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change Everything",
  "url": "https://urgent.news/2026/11/16/where-will-exelixis-be-in-5-years-1-experimental-drug-could-change",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-16T21:32:02.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/11/16/where-will-exelixis-be-in-5-years-1-experimental-drug-could-change-everything/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Exelixis has delivered impressive growth over the past five years, largely driven by its blockbuster cancer drug Cabometyx. However, patent expiration could pose challenges in the near future. The company is betting on its promising pipeline candidate zanzalintinib to change the trajectory. Zanzalintinib shows early promise in treating colorectal cancer, a disease with high mortality rates. Early-stage data suggests the drug could improve overall survival rates for metastatic colorectal cancer patients. Despite modest survival benefits, zanzalintinib may face higher rates of adverse events compared to existing treatments. The drug is being investigated for other cancer types as well. If approved, zanzalintinib could generate substantial sales, potentially offsetting the loss of revenue from Cabometyx after its patent expires in 2030. Exelixis is also exploring other pipeline candidates that could bolster its future revenue. Currently trading at a lower valuation compared to healthcare stocks, Exelixis' shares may present an attractive opportunity for investors seeking growth potential in the oncology sector.",
  "summary": "Exelixis’ leading pipeline candidate is inching closer to approval.",
  "key_points": [
    "Exelixis grew 5 years with Cabometyx as blockbuster cancer drug",
    "Patent expiration of Cabometyx could challenge future growth",
    "Zanzalintinib shows promise in treating colorectal cancer"
  ],
  "editors_take": "Betting on zanzalintinib represents a critical attempt to replace expiring patent revenue and maintain growth through a new oncology candidate that targets high-mortality colorectal cancer patients.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}